© 2025 MJH Life Sciences™ and The Center for Biosimilars - Biosimilars, Health Economics & Insights. All rights reserved.
Latest Conference Articles
Biosimilar Pegfilgrastim Can Increase Access, but Patient Perception Remains a Biosimilar Barrier
Kelly Davio
June 3 2019
During the 2019 American Society of Clinical Oncology Annual Meeting, researchers said that, for payers with large populations, the discounted biosimilar pegfilgrastim can produce substantial cost savings that can be applied to offer increased access to supportive care.
No Significant Difference in EFS, OS Between Herceptin and Biosimilar, Ontruzant, at 3 Years
Kelly Davio
June 3 2019
Between patients treated with the biosimilar and those treated with the reference product who were not exposed to lots of Herceptin with lower antibody-dependent cell-mediated cytotoxicity, no difference was observed in event-free survival (EFS) or overall survival (OS).
Biosimilar Monotherapy Sequence for RA Can Be Considered Cost-Effective, Study Finds
The Center for Biosimilars Staff
May 21 2019
Rheumatoid arthritis (RA) has a considerable economic burden, and costly biologics, are often restricted to cases in which patients fail to respond adequately to methotrexate or other conventional disease-modifying antirheumatic drugs, which may be difficult for some patients to tolerate.
Researchers Predict Substantial Savings for Europe on the Strength of Biosimilar Adalimumab
Kelly Davio
May 21 2019
During the ISPOR 2019 annual meeting, teams of investigators presented data estimating just how much healthcare systems could save by adopting biosimilar adalimumab for all indications of its reference in adult patients. The results highlighted both the scale of potential savings and the variability among European nations.
Health Plan Restrictions Likely to Have an Impact on Biosimilars, Orphan Drugs
Kelly Davio
May 20 2019
Despite their benefits to patients, innovative treatments, including biologics, come at a high cost to the healthcare system, and those in a position to make coverage decisions for these products must grapple with these therapies’ affordability. During the ISPOR 2019 meeting, researchers presented findings on how health plan restrictions could limit orphan drug coverage—and encourage biosimilar use—as a means to manage their budgets.
Researchers Present Findings on Patient Preferences, Outcomes With G-CSFs
The Center for Biosimilars Staff
May 18 2019
During this week’s meeting of the International Society for Pharmacoeconomic and Outcomes Research, held from May 18 to 22 in New Orleans, Louisiana, researchers presented findings on both the patient attitudes toward granulocyte colony-stimulating factor (G-CSF) therapies and their effectiveness in the prophylaxis of febrile neutropenia.